Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Big Pharma Is Paying More, Earlier For Biotechs

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Acquisition deals become more expensive as pharmas compete to fill pipelines, execs say at BIO meeting in Boston.

You may also be interested in...



Merck Outlines Its Criteria For Biotech Deals

CEO describes the criteria Merck is using to evaluate a potential biotech acquisition at JP Morgan Healthcare Conference.

Merck Outlines Its Criteria For Biotech Deals

CEO describes the criteria Merck is using to evaluate a potential biotech acquisition at JP Morgan Healthcare Conference.

Adnexus Buy Aimed At Enhancing Bristol’s Transformation To Biopharma Business

Acquisition valued at $430 million comes seven months after firms signed oncology development deal, which "exceeded our expectations," Bristol told "The Pink Sheet" DAILY.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS066138

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By